We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Much You'd Have If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago
Read MoreHide Full Article
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in Catalyst Pharmaceutical (CPRX - Free Report) ten years ago? It may not have been easy to hold on to CPRX for all that time, but if you did, how much would your investment be worth today?
Catalyst Pharmaceutical's Business In-Depth
With that in mind, let's take a look at Catalyst Pharmaceutical's main business drivers.
Coral Gables, FL-based Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, focused on the development and commercialization of therapies targeting rare and difficult-to-treat diseases.
In October 2012, Catalyst in-licensed rights to Firdapse (amifampridine phosphate) from BioMarin Pharmaceutical Inc. to develop and commercialize the product in the United States. Firdapse is currently approved in the European Union as well as in the United States for the symptomatic treatment of LEMS in adults.
The company is also strengthening the commercial portfolio of Firdapse. It already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population. As a result, these patents will now provide intellectual property protection to Firdapse through 2034.
Catalyst also received FDA approval in September 2022 for its supplemental new drug application (sNDA) for Firdapse (amifampridine) tablets in 10 mg dosage to include pediatric patients (six years and older) for treating LEMS. In May, the FDA approved the company’s sNDA seeking to increase the maximum dosage strength of Firdapse from 80 mg to 100 mg for LEMS.
In January 2023, Catalyst announced the successful acquisition of the U.S. rights for Fycompa (perampanel) CIII, from Eisai Co., Ltd. This has now diversified Catalyst’s portfolio with the addition of a commercial-stage epilepsy asset. Catalyst began marketing the product through its own sales organization in May 2023. In July 2023, the company also acquired North American rights to Santhera’s vamorolone, an investigational dissociative steroid, which has been approved by the FDA and consequently launched for the treatment of Duchenne Muscular Dystrophy (DMD), under the brand name Agamree.
Catalyst currently expects to attribute its future development costs, principally toward the continued development of Firdapse, Fycompa and Agamree. However, the company is currently focusing on acquiring the rights to late-stage products to treat rare central nervous system and adjacent rare diseases, as part of its efforts to diversify its business, as well as invest in innovative opportunities.
Catalyst recorded total revenues worth $398.2 million in 2023, reflecting an increase of 85.3% year over year.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Catalyst Pharmaceutical, if you bought shares a decade ago, you're likely feeling really good about your investment today.
According to our calculations, a $1000 investment made in August 2014 would be worth $8,770.93, or a 777.09% gain, as of August 16, 2024. Investors should keep in mind that this return excludes dividends but includes price appreciation.
In comparison, the S&P 500 gained 183.53% and the price of gold went up 80.83% over the same time frame.
Analysts are forecasting more upside for CPRX too. Catalyst beats second-quarter earnings and revenue estimates, driven by strong Firdapse sales. The drug, approved for treating Lambert-Eaton Myasthenic Syndrome (LEMS), an ultra-rare disease, has witnessed strong uptake since its launch. It is also approved for pediatric patients. The FDA recently increased the approved dosage strength of Firdapse from 80 mg to 100 mg, which should boost sales. The company also markets Fycompa CIII, a rare epilepsy drug, which has been generating incremental revenues. Agamree, its newest acquired muscle disorder drug, was recently launched in the U.S. market. This has created yet another revenue stream for the company. However, the company’s overdependence on Firdapse sales for revenues is concerning. Any developmental/regulatory setback for Firdapse will hurt the stock. Catalyst’s shares have outperformed the industry in the past year. Over the past four weeks, shares have rallied 19.08%, and there have been 4 higher earnings estimate revisions in the past two months for fiscal 2024 compared to none lower. The consensus estimate has moved up as well.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's How Much You'd Have If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in Catalyst Pharmaceutical (CPRX - Free Report) ten years ago? It may not have been easy to hold on to CPRX for all that time, but if you did, how much would your investment be worth today?
Catalyst Pharmaceutical's Business In-Depth
With that in mind, let's take a look at Catalyst Pharmaceutical's main business drivers.
Coral Gables, FL-based Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, focused on the development and commercialization of therapies targeting rare and difficult-to-treat diseases.
In October 2012, Catalyst in-licensed rights to Firdapse (amifampridine phosphate) from BioMarin Pharmaceutical Inc. to develop and commercialize the product in the United States. Firdapse is currently approved in the European Union as well as in the United States for the symptomatic treatment of LEMS in adults.
The company is also strengthening the commercial portfolio of Firdapse. It already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population. As a result, these patents will now provide intellectual property protection to Firdapse through 2034.
Catalyst also received FDA approval in September 2022 for its supplemental new drug application (sNDA) for Firdapse (amifampridine) tablets in 10 mg dosage to include pediatric patients (six years and older) for treating LEMS. In May, the FDA approved the company’s sNDA seeking to increase the maximum dosage strength of Firdapse from 80 mg to 100 mg for LEMS.
In January 2023, Catalyst announced the successful acquisition of the U.S. rights for Fycompa (perampanel) CIII, from Eisai Co., Ltd. This has now diversified Catalyst’s portfolio with the addition of a commercial-stage epilepsy asset. Catalyst began marketing the product through its own sales organization in May 2023. In July 2023, the company also acquired North American rights to Santhera’s vamorolone, an investigational dissociative steroid, which has been approved by the FDA and consequently launched for the treatment of Duchenne Muscular Dystrophy (DMD), under the brand name Agamree.
Catalyst currently expects to attribute its future development costs, principally toward the continued development of Firdapse, Fycompa and Agamree. However, the company is currently focusing on acquiring the rights to late-stage products to treat rare central nervous system and adjacent rare diseases, as part of its efforts to diversify its business, as well as invest in innovative opportunities.
Catalyst recorded total revenues worth $398.2 million in 2023, reflecting an increase of 85.3% year over year.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Catalyst Pharmaceutical, if you bought shares a decade ago, you're likely feeling really good about your investment today.
According to our calculations, a $1000 investment made in August 2014 would be worth $8,770.93, or a 777.09% gain, as of August 16, 2024. Investors should keep in mind that this return excludes dividends but includes price appreciation.
In comparison, the S&P 500 gained 183.53% and the price of gold went up 80.83% over the same time frame.
Analysts are forecasting more upside for CPRX too. Catalyst beats second-quarter earnings and revenue estimates, driven by strong Firdapse sales. The drug, approved for treating Lambert-Eaton Myasthenic Syndrome (LEMS), an ultra-rare disease, has witnessed strong uptake since its launch. It is also approved for pediatric patients. The FDA recently increased the approved dosage strength of Firdapse from 80 mg to 100 mg, which should boost sales. The company also markets Fycompa CIII, a rare epilepsy drug, which has been generating incremental revenues. Agamree, its newest acquired muscle disorder drug, was recently launched in the U.S. market. This has created yet another revenue stream for the company. However, the company’s overdependence on Firdapse sales for revenues is concerning. Any developmental/regulatory setback for Firdapse will hurt the stock. Catalyst’s shares have outperformed the industry in the past year.
Over the past four weeks, shares have rallied 19.08%, and there have been 4 higher earnings estimate revisions in the past two months for fiscal 2024 compared to none lower. The consensus estimate has moved up as well.